Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
During the past 12 months, GlaxoSmithKline Pharmaceuticals's average EBITDA Per Share Growth Rate was 12.00% per year.
During the past 3 years, the average EBITDA Per Share Growth Rate was 17.70% per year.
During the past 5 years, the average EBITDA Per Share Growth Rate was 20.00% per year.
During the past 10 years, the average EBITDA Per Share Growth Rate was 10.10% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.
During the past 13 years, the highest 3-Year average EBITDA Per Share Growth Rate of GlaxoSmithKline Pharmaceuticals was 31.90% per year. The lowest was -10.90% per year. And the median was 6.60% per year.
EBITDA per Share is the amount of Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) per outstanding share of the company's stock.
Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) is what the company earns before it expenses interest, taxes, depreciation and amortization.
5-Year EBITDA Growth Rate gives an overview of the company's growth in operating profitability and is an important factor used in calculating Peter Lynch Fair Value.
GlaxoSmithKline Pharmaceuticals 5-Year EBITDA Growth Rate Related Terms
NSE:GLAXO vs LLY, JNJ, ABBV: 5-Year EBITDA Growth Rate Comparison
For the Drug Manufacturers - General subindustry, GlaxoSmithKline Pharmaceuticals's 5-Year EBITDA Growth Rate, along with its competitors' market caps and 5-Year EBITDA Growth Rate data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
GlaxoSmithKline Pharmaceuticals 5-Year EBITDA Growth Rate vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, GlaxoSmithKline Pharmaceuticals's 5-Year EBITDA Growth Rate distribution charts can be found below:
* The bar in red indicates where GlaxoSmithKline Pharmaceuticals's 5-Year EBITDA Growth Rate falls into.
This is the 5-year average growth rate of EBITDA per Share. The growth rate is calculated with least square regression.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.
What does a 5-Year EBITDA Growth Rate of 20.00% mean?
GlaxoSmithKline Pharmaceuticals (NSE:GLAXO) has a 5-Year EBITDA Growth Rate of 20.00% as of Jun. 2026. 5-Year EBITDA Growth Rate is the 5-year average growth rate of EBITDA per share. View historical data for GlaxoSmithKline Pharmaceuticals and its competitors.
Is GlaxoSmithKline Pharmaceuticals' 5-Year EBITDA Growth Rate too high?
GlaxoSmithKline Pharmaceuticals' current 5-Year EBITDA Growth Rate is 20.00%. Overall, GlaxoSmithKline Pharmaceuticals has a GF Score™ of 78/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does GlaxoSmithKline Pharmaceuticals' 5-Year EBITDA Growth Rate compare to LLY and JNJ?
GlaxoSmithKline Pharmaceuticals' 5-Year EBITDA Growth Rate of 20.00% can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 5-Year EBITDA Growth Rate for a Drug Manufacturers company?
A good 5-Year EBITDA Growth Rate depends on the Drug Manufacturers industry context. However, 5-Year EBITDA Growth Rate should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 5-Year EBITDA Growth Rate mean?
A high 5-Year EBITDA Growth Rate can signal that a stock is expensive relative to its fundamentals. 5-Year EBITDA Growth Rate is the 5-year average growth rate of EBITDA per share. View historical data for GlaxoSmithKline Pharmaceuticals and its competitors. GlaxoSmithKline Pharmaceuticals's current 5-Year EBITDA Growth Rate is 20.00%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is GlaxoSmithKline Pharmaceuticals stock overvalued right now?
Based on GuruFocus' analysis, GlaxoSmithKline Pharmaceuticals (NSE:GLAXO) is currently considered Fairly Valued. The stock's GF Value™ is ₹2,727.86, compared to a current price of ₹2,931.70 — trading 7.5% above its estimated fair value. The current 5-Year EBITDA Growth Rate is 20.00%. GlaxoSmithKline Pharmaceuticals' overall GF Score™ is 78/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 5-Year EBITDA Growth Rate calculated?
5-Year EBITDA Growth Rate is calculated from a company's financial statements. For GlaxoSmithKline Pharmaceuticals (NSE:GLAXO), the current 5-Year EBITDA Growth Rate is 20.00% as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is GlaxoSmithKline Pharmaceuticals (NSE:GLAXO) Overvalued in 2026?
Based on GuruFocus' analysis, GlaxoSmithKline Pharmaceuticals stock appears to be overvalued.
The current stock price of ₹2,931.70 is trading 7.5% above its estimated GF Value™ of ₹2,727.86.
GuruFocus considers GlaxoSmithKline Pharmaceuticals to be Fairly Valued.
Key valuation signals for NSE:GLAXO:
5-Year EBITDA Growth Rate: 20.00%
GF Value™: ₹2,727.86 vs. price of ₹2,931.70 (7.5% above fair value)
No single metric tells the full story. See the NSE:GLAXO stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
GlaxoSmithKline Pharmaceuticals Ltd is engaged interalia, in the business of manufacturing, distributing and trading in pharmaceuticals. It is healthcare organisation focused on uniting science, technology and talent to get ahead of disease. The company's product portfolio comprises a broad range of General Medicines which includes anti-infectives, pain management, vitamins, minerals, nutritionals, hormones, dermatologicals, vaccines for both children and adults, and specialty medicines for respiratory and oncology. Its focused brands are Augmentin, Ceftum, Flutivate, T-bat, Betnovate, Neosporin, Tenovate, Physiogel, Calpol and Calpol T. The company has single reportable segment. The company has presence in India, and also Outside India. It generates majority of revenue from India.
78GF Score
Get the complete analysis for NSE:GLAXO
5-Year EBITDA Growth Rate is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
NSE:GLAXO has been successfully added to your 
